Tiangang Li

Associate Professor

University of Oklahoma Health Sciences Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Tiangang Li is an Associate Professor at the University of Oklahoma Health Sciences Center in the United States. His research focuses on bile acid metabolism, liver physiology, and the molecular mechanisms underlying liver diseases. Recent articles authored by Dr. Li explore topics such as hepatic injury modulation, cellular stress responses related to bile acids, and therapeutic interventions in non-alcoholic steatohepatitis.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Feng Li

Associate Professor

Baylor College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tiangang Li

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Gly-βMCA modulates bile acid metabolism to reduce hepatobiliary injury in Mdr2 KO mice

Bile acid sequestrant inhibits gluconeogenesis via inducing hepatic cysteine dioxygenase type 1 to reduce cysteine availability

Bile acids regulation of cellular stress responses in liver physiology and diseases

Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance

Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis

Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization

Liver-specific microRNA-185 knockout promotes cholesterol dysregulation in mice

Gut‐restricted apical sodium‐dependent bile acid transporter inhibitor attenuates alcohol‐induced liver steatosis and injury in mice

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis

Collaborators (1)

Feng Li

Make your next move.